Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.12% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
TGTX · Jun 30, 2026
TG THERAPEUTICS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 4[email protected]
Inspectable configuration
State dimensions
Filing0001437749-26-025955General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
16.34% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
70.27% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
61.57% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
82.86% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
9.02% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
39.67% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
11.60% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History17 statesSelf-history eligible
Jun 30, 20220/7 normalizedLevel 3Sep 30, 20220/7 normalizedLevel 3Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/7 normalizedLevel 3Jun 30, 20235/7 normalizedLevel 3Sep 30, 20235/8 normalizedLevel 3Dec 31, 20235/9 normalizedLevel 3Mar 31, 20244/7 normalizedLevel 3Jun 30, 20245/7 normalizedLevel 3Sep 30, 20245/7 normalizedLevel 3Dec 31, 20246/8 normalizedLevel 3Mar 31, 20257/8 normalizedLevel 3Jun 30, 20257/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 0.02%
- Current
- 0.12%
- Delta
- 0.10%
- Previous
- -8.73%
- Current
- 16.34%
- Delta
- 25.07%
- Previous
- 69.56%
- Current
- 70.27%
- Delta
- 0.72%
- Previous
- 62.97%
- Current
- 61.57%
- Delta
- -1.40%
- Previous
- 83.65%
- Current
- 82.86%
- Delta
- -0.79%
- Previous
- 16.98%
- Current
- 9.02%
- Delta
- -7.96%
- Previous
- 23.62%
- Current
- 39.67%
- Delta
- 16.05%
- Previous
- 9.74%
- Current
- 11.60%
- Delta
- 1.86%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
- Similarity
- 84%
- Compared
- 8 dimensions
- Coverage
- 100%
- Similarity
- 79%
- Compared
- 6 dimensions
- Coverage
- 75%
- Similarity
- 76%
- Compared
- 7 dimensions
- Coverage
- 88%
- Similarity
- 76%
- Compared
- 5 dimensions
- Coverage
- 63%
Research Graph
Related governed research
Analogous To · TGTX state analogue 2 →Analogous To · TGTX state analogue 1 →Analogous To · TGTX state analogue 4 →Compared To · Pharmaceutical Preparations peers →Analogous To · TGTX state analogue 3 →Transitioned To · TGTX Fundamental State →Transitioned To · TGTX CAPEX_INTENSITY_INCREASED →Transitioned To · TGTX CASH_GENERATION_INCREASED →Transitioned To · TGTX GROWTH_INCREASED →Transitioned To · TGTX INVENTORY_PRESSURE_DECREASED →Transitioned To · TGTX MARGIN_DECREASED →Transitioned To · TGTX PROFITABILITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.